Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


 

Corporate Information

Hemispherx Biopharma, Inc., headquartered in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to treating and preventing chronic viral and immune-based disorders through the development and manufacturing of compounds that enhance the natural immune system of the human body.

The Company’s flagship products include Alferon N Injection® and the experimental immunotherapeutics Ampligen® and Oragens®. Its platform technology includes large and small agents for potential treatment of various chronic viral infections.

Ampligen®, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted at such important diseases as Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), HIV, Hepatitis B, Hepatitis C, and cancers including kidney cancer and metastatic malignant melanoma.

Alferon N Injection® (interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multi-species alpha interferon product, composed of eight forms of high-purified alpha interferon.  It is the only natural source, multi-species alfa interferon currently sold in the United States and is also approved for sale in certain other countries, including Mexico, Germany, Hong Kong and Singapore.  Alferon N Injection® is the company’s registered trademark for it’s injectible formulation or natural alpha interferon approved by the FDA for the treatment of genital HPV (refractory condylomata acuminata).  Alferon N Injection® may also have activity against other viral infections such as Multiple Sclerosis, Hepatitis C, HIV, West Nile Virus, and SARS, but has not been approved for that use.

Hemispherx is also actively engaged in broad-based ongoing experimental studies assessing the efficacy of their products Ampligen®, Alferon N Injection® and Alferon LDO® against influenza viruses as an adjuvant and/or single agent antiviral with the Defence R&D Canada, the National Institute of Infectious Diseases in Tokyo, the Princess Margaret Hospital in Hong Kong and various research affiliates of the National Institutes of Health in the United States.  Please visit our home page for the complete outline of our avian influenza programs.